Metabolic effects of switching to Biktarvy (B/F/ TAF ) in patients with HIV ‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate ( TDF ) or tenofovir alafenamide ( TAF ): The Metabic study
HIV Medicine · 2024
DOI: 10.1111/hiv.13659 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV Medicine, 2024. Verfasst von C Busca-Arenzana und 10 weiteren Autor:innen. Beteiligte Einrichtung: HIV Unit, Hospital Universitario de La Paz-Carlos III, IdiPAZ, Madrid, Spain. Hauptthemen laut MEDLINE: HIV Infections, Tenofovir, Alanine, Anti-HIV Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Background
Studies on switching to tenofovir alafenamide (TAF)‐based regimens raise concerns about a worse metabolic profile in people with HIV, even though most received tenofovir disoproxil fumarate (TDF) in their previous regimen. This study aims to evaluate changes in lipid fractions, glucose, and serum markers for hepatic steatosis (HS) after switching from a TDF‐ or TAF‐sparing regimen to bictegravir/emtricitabine/TAF (B/F/TAF).
Methods
We performed a retrospective cohort study of people with HIV who switched to B/F/TAF from TDF‐ or TAF‐sparing regimens between January 2019 and May 2022 with at least 6 months of follow‐up. The primary endpoint was the absolute change in lipid fractions at 6 months. Secondary outcomes were changes in lipid fractions at 12 months and changes in other metabolic parameters (glucose, creatinine, and HS based on the triglyceride‐to‐glucose [TyG] ratio at 6 and 12 months). Changes were analysed using mixed linear regression models with random intercept and time as a fixed effect.
Results
The study included 259 people with HIV (median age 55 [interquartile range (IQR) 47–60] years; 80% male; 88% Caucasian; CD4+ T‐cell count 675 [IQR 450–880] cells/mm 3 ; 84.3% HIV‐RNA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HIV Unit, Hospital Universitario de La Paz-Carlos III, IdiPAZ, Madrid, Spain.
- CIBER de Enfermedades Infecciosas CIBER INFEC, Instituto de Salud Carlos III, Madrid, Spain.
- Biostatistics Unit, La Paz Research Institute, IdiPAZ, Madrid, Spain.
ORCID-Profile: L Ramos-Ruperto, Jose I Bernardino
Zitieren
APA
Busca-Arenzana, C., Ortega-González, D., Díaz-Almirón, M., Montes, M. L., Martin-Carbonero, L., Mican, R., Montejano, R., Ramos-Ruperto, L., Valencia, E., Delgado-Hierro, A., & Bernardino, J. I. (2024). Metabolic effects of switching to Biktarvy (B/F/ TAF ) in patients with HIV ‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate ( TDF ) or tenofovir alafenamide ( TAF ): The Metabic study. HIV Medicine. https://doi.org/10.1111/hiv.13659
Vancouver
Busca-Arenzana C, Ortega-González D, Díaz-Almirón M, Montes ML, Martin-Carbonero L, Mican R, et al. Metabolic effects of switching to Biktarvy (B/F/ TAF ) in patients with HIV ‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate ( TDF ) or tenofovir alafenamide ( TAF ): The Metabic study. HIV Medicine. 2024. doi:10.1111/hiv.13659
BibTeX
@article{BuscaArenzana2024,
author = {Busca-Arenzana, C and Ortega-González, D and Díaz-Almirón, M and Montes, M L and Martin-Carbonero, Luz and Mican, R and Montejano, R and Ramos-Ruperto, L and Valencia, Eulalia and Delgado-Hierro, Ana and Bernardino, Jose I},
title = {Metabolic effects of switching to Biktarvy (B/F/ TAF ) in patients with HIV ‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate ( TDF ) or tenofovir alafenamide ( TAF ): The Metabic study},
journal = {HIV Medicine},
year = {2024},
doi = {10.1111/hiv.13659}
}
EUVIMED